Patents by Inventor Andreas Goutopoulos

Andreas Goutopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250002491
    Abstract: The present invention relates to a compound of formula (I) as PARC inhibitors for the treatment of proliferative disorders, such as e.g. cancer. Preferred compounds are e.g. N,N-dimethyl-4-(7-(N-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl) piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives, such as e.g. the present example 1, N,N-dimethyl-4-(7-(N-(1-methyl-cyclopropyl)sulfamoyl)-1-(6-methylpyridin-3-yl)imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide (II). Experimental data of PARC inhibition assays of exemplary compounds is provided.
    Type: Application
    Filed: October 3, 2022
    Publication date: January 2, 2025
    Applicant: FORX THERAPEUTICS AG
    Inventors: Ulrich Luecking, Andreas Goutopoulos, Jin Tian, Sotirios Sotiriou, Luca Iacovino, Alena Freudenmann, Olivier Querolle
  • Publication number: 20240425498
    Abstract: The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form, pharmaceutically acceptable salt or a prodrug thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. Instant compounds are particularly useful as PARC inhibitors, and can be used in a method of treatment of a proliferative disorder, preferably of cancer.
    Type: Application
    Filed: October 3, 2022
    Publication date: December 26, 2024
    Applicant: FORX THERAPEUTICS AG
    Inventors: Ulrich Luecking, Andreas Goutopoulos, Jin Tian, Sotirios Sotiriou, Luca Iacovino, Alena Freudenmann, Olivier Querolle
  • Patent number: 12133852
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: November 5, 2024
    Assignee: EpiVario, Inc.
    Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
  • Publication number: 20230174507
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Application
    Filed: May 12, 2021
    Publication date: June 8, 2023
    Applicant: METABOMED LTD.
    Inventors: Philippe NAKACHE, Omri EREZ, Simone BOTTI, Andreas GOUTOPOULOS, Harry Finch
  • Publication number: 20230084752
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.
    Type: Application
    Filed: May 14, 2020
    Publication date: March 16, 2023
    Applicant: Metabomed Ltd.
    Inventors: Philippe NAKACHE, Omri Erez, Simone BOTTI, Andreas GOUTOPOULOS, Harry Finch
  • Publication number: 20230084927
    Abstract: The present invention relates to novel compounds that modulate cellular glucose uptake by affecting various targets, including, but not limited to those related to glycolysis and known transporters/co-transporters of the GLUT family. The compounds according to the invention are useful for treating cancer such as: neuroendocrine neoplasms, gastrointestinal stromal tumors (GIST), renal cell carcinoma, paraganglioma, pheochromocytoma, pituitary adenoma, colorectal cancer, lung cancer, gastric cancer, pancreatic cancer sarcoma, head and neck cancer, melanoma, ovarian cancer and other cancers that rely on high levels of glycolysis for survival and proliferation; as well as in treating of autoimmune diseases, inflammation, infectious diseases, and metabolic diseases.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 16, 2023
    Applicant: METABOMED LTD.
    Inventors: Philippe NAKACHE, Omri EREZ, Simone BOTTI, Andreas GOUTOPOULOS
  • Publication number: 20220305010
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Application
    Filed: November 4, 2020
    Publication date: September 29, 2022
    Applicant: METABOMED LTD.
    Inventors: Philippe NAKACHE, Omri Erez, Simone Botti, Andreas Goutopoulos
  • Patent number: 11098041
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Patent number: 10851064
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: December 1, 2020
    Assignee: METABOMED LTD.
    Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
  • Patent number: 10517872
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos
  • Patent number: 10413562
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 17, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Publication number: 20190263758
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 29, 2019
    Applicant: METABOMED LTD.
    Inventors: Philippe NAKACHE, Omri EREZ, Simone BOTTI, Andreas GOUTOPOULOS
  • Publication number: 20190233417
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Patent number: 10253023
    Abstract: The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: April 9, 2019
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Patent number: 10233160
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: March 19, 2019
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste DeSelm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Publication number: 20180243324
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER
  • Publication number: 20180237402
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Application
    Filed: April 24, 2018
    Publication date: August 23, 2018
    Inventors: Bayard R. HUCK, Ruoxi LAN, Justin POTNICK, Lizbeth Celeste DESELM, Mark W. CRONIN, JR., Constantin NEAGU, Xiaoling CHEN, Roch BOIVIN, Theresa L. JOHNSON, Andreas GOUTOPOULOS
  • Patent number: 10016448
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Patent number: 9981925
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste Deselm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Patent number: 9938262
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R7, R6, X and Y have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Andreas Goutopoulos, Thomas E. Richardson, Jiezhen Li, Brian H. Heasley, Pandi Bharathi